药店买药，医保价反而更贵？医保局严查整治“阴阳价格”

Core Viewpoint - The article highlights the issue of "yin-yang pricing" in designated retail pharmacies, where the same medication is sold at a higher price to insured patients compared to those paying out-of-pocket, prompting the National Healthcare Security Administration (NHSA) to take action against this practice [3][4][5]. Group 1: Issue Identification - "Yin-yang pricing" is identified as a discriminatory pricing behavior where designated pharmacies charge insured patients more than non-insured patients for the same medication [3][4]. - The NHSA has classified this practice as price fraud, violating agreements that prohibit unfair pricing for insured individuals [3][5]. Group 2: Regulatory Response - The NHSA has issued a notification requiring local healthcare departments to investigate and manage the "yin-yang pricing" issue, emphasizing the need for regular monitoring of drug prices in designated pharmacies [3][6]. - The notification encourages the public to report instances of "yin-yang pricing" to assist in the enforcement of regulations [5][6]. Group 3: Challenges and Recommendations - Experts note that the difficulty in price regulation stems from the large number of retail pharmacies and frequent price changes, making comprehensive monitoring challenging [4][5]. - Recommendations include enhancing market monitoring, improving the transparency of pricing, and utilizing big data to identify pharmacies with significant price discrepancies [5][6]. Group 4: Enforcement Measures - The NHSA has outlined strict penalties for pharmacies found engaging in "yin-yang pricing," ranging from warnings to suspension of their healthcare settlement qualifications [6][7]. - Ongoing management of drug prices in designated pharmacies is emphasized, including the use of price comparison tools and regular audits of high-risk drug categories [7][8].